# Daily **Note**

Views, news and topics from today's markets

CANTOR Fitzgerald

Friday, 28th June 2019

## **Morning Round Up**

## Bank of Ireland to sell UK credit card operation

Bank of Ireland's UK unit has agreed to sell its existing UK credit cards portfolio for c.£530m to CCP Credit Master Lux Sarl and CSCP III Master Lux Sarl. Both of which are special purpose investment vehicles advised by affiliates of Centerbridge Partners Europe LLP and Jaja Finance Limited. The portfolio comprises of the Post Office, the AA and the Bank of Ireland's branded consumer credit cards. The sale, which has been well flagged, removes the high cost drag on UK profitability and boosts the CET1 capital position. Last year this card portfolio accounted for c.1% of group revenue but given its lack of profitability the sale will have little affect on bottom line earnings for the group. Despite this, the stock is trading down 2% this morning.


#### Nike misses expectations for the first time in seven years

Nike released Q4/19 results after market close yesterday, missing earnings expectations for the first time since 2012. However, management reiterated guidance for the coming year and blamed higher overhead expenses, tax and FX for the miss. The reassurance meant the stock price recovered in after hours trading following an initial 4.9% drop. Importantly, Nike's revenue met expectations rising by 10% from a constant currency perspective and 4% as reported. Performance was strong across all regions, led by innovation. Digital sales grew by 35% and are now expected to account for 30% of revenue by 2023. Profitability improved as gross margin expanded by 80bps. Nike has yet to be really hit by trade uncertainties. Unlike some of its competitors its exposure to the trade spat is somewhat limited. Only c.26% of its footwear and apparel were made in China last year, of which only 10% was exported to the US.

## Walgreens gains on earnings beat

Walgreen's rose by 4% yesterday following a better than expected set of Q3 results. However, earnings fell by 3.9% despite revenue rising by 0.75% as higher costs weighed on profitability. Importantly management reiterated its outlook from April for flat earnings for the remained of the year, implying an improvement in the fourth quarter. Despite trading at an attractive 9x FY19 P/E, the sector continues to face challenges and we would advise against buying into the stock at this time. Management is looking to improve the business model entering into partnerships with Kroger and Microsoft. Should they succeed there may be an entry point in the future.

#### Walgreens 5 year stock price



Source: Bloomberg, CF Research June 2019

## **Key Upcoming Events**

28-29/06/2019 G20 Summit 01-02/07/2019 OPEC meeting

## **Market View**

Equity markets are relatively flat this morning with lighter than average volumes as investors await the G20 meeting between Trump and Xi tomorrow. June has been a strange month for financial markets with equities, bonds, oil and gold all performing strongly. Saturdays meeting is likely to dominate market direction next week. Should there fail to be a truce and Trump subsequently enacts his "Plan B" by adding 10% tariffs on the \$300bn, risk assets will fall. On the economic data front yesterday, European Business confidence was its lowest since October 2014. Inflation data from both Europe and the US will be important today, given the soft stance taken by central banks.

Market Moves				
	Value	Change	% Change	% Change YTD
Dow Jones	26537	-11.40	-0.04%	13.81%
S&P	2914	-3.60	-0.12%	16.38%
Nasdaq	7910	25.25	0.32%	18.83%
Nikkei	21338	251.58	1.19%	6.61%
Hang Seng	28621	399.44	1.42%	9.19%
Brent Oil	65.89	-0.60	-0.90%	22.47%
WTI Oil	58.97	-0.41	-0.69%	29.86%
Gold	1404	-5.17	-0.37%	9.69%
€/\$	1.1369	0.0000	0.00%	-0.85%
€/£	0.8959	-0.0002	0.02%	0.34%
£/\$	1.2691	0.0001	0.01%	-0.49%
			Yield	Change
German 10 Year			-0.294	0.009
UK 10 Year			0.846	0.015
US 10 Year			2.054	0.007
Irish 10 Year			0.212	0.011
Spain 10 Year			0.40	0.008
Italy 10 Year			2.159	0.018

Daily **Note** Friday, 28<sup>th</sup> June 2019

## **Cantor Publications & Resources**



## Weekly Trader

On Mondays, we release our weekly note in which we provide a view on equity markets for the coming days, and highlight a number of equities which we believe provide exposure to the important themes unfolding in the markets. Our in-house Investment Committee meets on a weekly basis to craft this strategy, thereby allowing clients to dynamically position portfolios to take advantage of the most up to date market developments.

**Click Here** 



## Monthly Investment Journal

Each month our Private Client and Research departments collaborate to issue a publication which highlights the performance of our flagship products, funds and our Core Portfolio, including the Green Effects fund, most recent private equity deals and structured product investment opportunities.

**Click Here** 



## **Investment Forum**

Through our investment Forum we bring you the latest market news, investment insights and a series of informative articles from our experts.

**Click here** 

Daily **Note** Friday, 28<sup>th</sup> June 2019

## **Regulatory Information**

Issuer Descriptions: (Source: Bloomberg)

#### **Historical Recommendation:**

#### http://www.cantorfitzgerald.ie/research\_disclosures.php

This material is approved for distribution in Ireland by Cantor Fitzgerald Ireland Ltd. It is intended for Irish retails clients only and is not intended for distribution to, or use by, any person in any country where such distribution or use would be contrary to local law or regulation. Cantor Fitzgerald Ireland Ltd ("CFIL") is regulated by the Central Bank of Ireland. Cantor Fitzgerald Ireland Ltd is a member firm of the Irish Stock Exchange and the London Stock Exchange.

Where CFIL wishes to make this and other Cantor Fitzgerald research available to Retail clients, such information is provided without liability and in accordance with our terms and conditions that are available on the CFIL website.

No report is intended to and does not constitute a personal recommendations or investment advice nor does it provide the sole basis for any evaluation of the securities that may be the subject matter of the report. Specifically, the information contained in this report should not be taken as an offer or solicitation of investment advice, or to encourage the purchased or sale of any particular security. Not all recommendations are necessarily suitable for all investors and CFIL recommend that specific advice should always be sought prior to investment, based on the particular circumstances of the investor either from your CFIL investment adviser or another investment adviser.

CFIL takes all responsibility to ensure that reasonable efforts are made to present accurate information but CFIL gives no warranty or guarantee as to, and do not accept responsibility for, the correctness, completeness, timeliness or accuracy of the information provided or its transmission. This is entirely at the risk of the recipient of the report. Nor shall CFIL, its subsidiaries, affiliates or parent company or any of their employees, directors or agents, be liable to for any losses, damages, costs, claims, demands or expenses of any kind whatsoever, whether direct or indirect, suffered or incurred in consequence of any use of, or reliance upon, the information. Any person acting on the information contained in this report does so entirely at his or her own risk

All estimates, views and opinions included in this research note constitute CANTOR IRELAND's judgment as of the date of the note but may be subject to change without notice. Changes to assumptions may have a material impact on any recommendations made herein.

Unless specifically indicated to the contrary this research note has not been disclosed to the covered issuer(s) in advance of publication.

Past performance is not a reliable guide to future performance. The value of your investment may go down as well as up. Investments denominated in foreign currencies are subject to fluctuations in exchange rates, which may have an adverse affect on the value of the investments, sale proceeds, and on dividend or interest income. The income you get from your investment may go down as well as up. Figures quoted are estimates only; they are not a reliable guide to the future performance of this investment.

#### Conflicts of Interest & Share Ownership Policy

It is noted that research analysts' compensation is impacted upon by overall firm profitability and accordingly may be affected to some extent by revenues arising other CANTOR IRELAND business units including Fund Management and Stock broking. Revenues in these business units may derive in part from the recommendations or views in this report. Notwithstanding, CANTOR IRELAND is satisfied that the objectivity of views and recommendations contained in this note has not been compromised. Nonetheless CANTOR IRELAND is satisfied that the impartiality of research, views and recommendations remains assured.

#### **Analyst Certification**

Each research analyst responsible for the content of this research note, in whole or in part, certifies that: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research note.



**Dublin:** 75 St. Stephen's Green, Dublin 2. Tel: +353 1 633 3633.

email: ireland@cantor.com web: www.cantorfitzgerald.ie

Twitter: @cantorIreland Linkedin: Cantor Fitzgerald Ireland